Nuevolution Announces New Research Collaboration With Big PharmaAugust 30th, 2009 COPENHAGEN -
- Partnership to use Nuevolution's Chemetics(R) Technology for Lead Discovery
Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis. During the collaboration, Nuevolution will apply its proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against drug targets of interest to Novartis.
Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461August 17th, 2009 SAN DIEGO -
Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S.
EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual PropertyAugust 3rd, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSKJuly 27th, 2009 COPENHAGEN, Denmark - Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline. The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads.
EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its CreditorsJuly 21st, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory DiseasesJune 29th, 2009 SAN DIEGO -
- Results Demonstrate Positive Proof of Mechanism
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.
O2h and Hypoxium Announce an Agreement to Offer Hypoxium's Specialised In Vitro, Cell-Based Oncology Assays via O2h's Biology Affiliate ProgramJune 24th, 2009 CAMBRIDGE, England - O2h has initiated a networked approach towards being a full service discovery services company at the forefront of drug discovery research. O2h has established a new biology lab on-site in Ahmedabad, India offering physio-chemical and CYP450 assays.
Jubilant to Work With Endo Pharmaceuticals on Drug DevelopmentJune 10th, 2009 NOIDA, India - Collaboration to Provide Endo Pharmaceuticals With New Drug Candidates in Oncology
Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.
BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery ServicesApril 5th, 2009 BEIJING - BioDuro announced today that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche's global research sites. BioDuro will provide research services in the areas of discovery chemistry and biology, which can help to shorten (internal) drug discovery timelines.
Nuevolution Announces Progress in its Collaboration With Merck & Co. Inc.April 1st, 2009 COPENHAGEN - Nuevolution A/S today announced that Merck & Co. Inc. has chosen to proceed to the second phase of the collaboration agreement announced in June 2008 to apply Nuevolution's proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against several drug targets.
